BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.